----
Current ValuationThe current P/E ratio is -13.20, above the reasonable range, cheaper than 6.92% of the time in the past 1 years, and the industry ranks 53/84, the industry Median 19.89.
-13.2xP/E
¥9.21Stock price
¥-0.70Earnings per share
-13.2xP/E
Stock price¥9.21Earnings per share¥-0.70
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -15.76x
- Typical range
- -17.37x–-13.96x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 19.89x
023466992
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 19.89x
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
300122SZZHIFEI-BIOL | -2.29x | 91.91% | ¥32.29B |
688180SHJunshi Biosciences | -69.36x | 81.90% | ¥29.73B |
603392SHWantai Biological | -63.97x | 22.02% | ¥29.14B |
300676SZBGI Genomics | -28.34x | 118.23% | ¥15.44B |
688520SHSinocelltech | -15.26x | 171.21% | ¥14.62B |
688765SHHEALTHGEN BIOTECH | -76.59x | -- | ¥10.85B |
688319SHOlymvax Biopharmaceuticals | -332.72x | 227.87% | ¥10.65B |
688137SHNovoprotein | -108.89x | -- | ¥10.54B |
688806SHTrinomab Pharmaceutical | -21.94x | -- | ¥9.88B |
300204SZStaidson BioPharm | -90.98x | -- | ¥9.06B |
688062SHMabwell | -8.52x | 37.63% | ¥8.95B |
688443SHGenrix Bio | -40.50x | 32.19% | ¥8.48B |
002030SZDAJY | -9.78x | -- | ¥7.27B |
688382SHInventisBio | -18.94x | 5.45% | ¥7.18B |
300294SZBOYA BIOLOGY | -40.93x | 281.82% | ¥6.87B |
688759SHBeBetter Med | -34.50x | 12.50% | ¥6.82B |
688177SHBIO-THERA | -15.36x | 2.47% | ¥6.77B |
688276SHBCHT | -31.92x | 66.67% | ¥6.38B |
002038SZSL PHARM | -6.10x | -- | ¥5.12B |
688221SHFroniter Biotechnologies | -133.06x | -- | ¥4.76B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
